{
    "clinical_study": {
        "@rank": "8364", 
        "acronym": "TOP MRI", 
        "arm_group": [
            {
                "arm_group_label": "Topiramate", 
                "arm_group_type": "Experimental", 
                "description": "up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI) to\n      examine the effects of topiramate on brain and behavioral responses in heavy drinkers to\n      appetitive alcohol reminders (cues that motivate continued alcohol use and relapse). This\n      project will yield novel findings on brain and behavioral responses to alcohol cues, the\n      effects of topiramate on alcohol cue reactivity, and the mechanisms underlying topiramate's\n      ability to blunt alcohol cue reactivity and heavy drinking."
        }, 
        "brief_title": "Topiramate's Effects on Heavy Drinking", 
        "completion_date": {
            "#text": "September 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Alcohol Drinking", 
        "condition_browse": {
            "mesh_term": "Alcohol Drinking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Physically healthy, as determined by a comprehensive physical examination and\n             approval of the study physician, males or females who drink alcohol, ages 18-60.\n\n          -  Average weekly ethanol consumption of >24 standard drinks for men, or >18 standard\n             drinks for women.\n\n          -  Females must be non-pregnant, non-lactating and either be of non-childbearing\n             potential (i.e. sterilized via hysterectomy or bilateral tubal ligation or at least 2\n             years postmenopausal) or of child bearing potential but practicing a medically\n             acceptable method of birth control. Examples of medically acceptable methods for this\n             protocol include: the birth control pill, intrauterine device, injection of\n             Depo-Provera, Norplant, contraceptive patch, contraceptive ring, double-barrier\n             methods (such as condoms and diaphragm/spermicide), male partner sterilization,\n             abstinence (and agreement to continue abstinence or to use an acceptable method of\n             contraception, as listed above, should sexual activity commence), and tubal ligation.\n\n          -  Provide voluntary informed consent.\n\n          -  Must be able to read. [Subjects are required to be able to read because there are\n             several self-administered measures that they must read, understand and provide\n             written answers.]\n\n          -  Intelligence quotient of \u2265 80.\n\n        Exclusion Criteria:\n\n          -  Current, clinically significant physical disease or abnormality on the basis of\n             medical history, physical examination, or routine laboratory evaluation.\n\n          -  History of head trauma or injury causing loss of consciousness, lasting more than\n             five (5) minutes or associated with skull fracture or inter-cranial bleeding or\n             abnormal MRI.\n\n          -  Current major DSM-IV Axis I diagnoses other than alcohol use disorder (except\n             nicotine use disorder).\n\n          -  Presence of magnetically active irremovable prosthetics, plates, pins, permanent\n             retainer, bullets, etc. (unless a radiologist confirms that it's presence is\n             unproblematic). An x-ray may be obtained to determine eligibility given the\n             possibility of a foreign body.\n\n          -  History of a serious psychiatric illness including psychosis, bipolar disorder, or\n             suicidal or homicidal intent.\n\n          -  Current treatment with carbonic anhydrase inhibitors.\n\n          -  Claustrophobia or other medical condition preventing subject from lying in the MRI\n             for approximately one (1) hour.\n\n          -  Current regular treatment with psychotropic medications (e.g., benzodiazepines,\n             antidepressants), which affect neurotransmitter systems or a medication being used to\n             treat alcohol use disorders (e.g., naltrexone, acamprosate).\n\n          -  Vision problems that cannot be corrected with glasses.\n\n          -  Body Mass Index (BMI) greater than or equal to 34, body girth greater than 52 inches\n             and a head girth greater than 25 inches.\n\n          -  History of stroke and/or stroke related spasticity.\n\n          -  History of glaucoma or kidney stones.\n\n          -  HIV positive.\n\n          -  History of seizures.\n\n          -  History of topiramate treatment for alcohol use disorder and report no treatment\n             response.\n\n          -  Current DSM-5 diagnosis of alcohol use disorder that is clinically too severe to\n             permit them to participate in a research trial in which the goal is to stop or reduce\n             drinking."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074904", 
            "org_study_id": "TOP MRI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Topiramate", 
                "intervention_name": "Topiramate", 
                "intervention_type": "Drug", 
                "other_name": "Topamax"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Topiramate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "University of Pennsylvania Center for Studies of Addiction"
            }, 
            "investigator": [
                {
                    "last_name": "Reagan R Wetherill, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Henry R Kranzler, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Brain Mechanisms of Topiramate's Effects on Heavy Drinking", 
        "overall_contact": {
            "email": "timpond@mail.med.upenn.edu", 
            "last_name": "Timothy Pond, MPH", 
            "phone": "215-222-3200", 
            "phone_ext": "241"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Pennsylvania", 
                "last_name": "Reagan R Wetherill, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Pennsylvania", 
                "last_name": "Henry R Kranzler, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "At baseline (prior to randomization), brain and behavioral responses will be significantly greater during alcohol cue exposure compared to non-alcohol cue exposure. Following 6 weeks of study drug, individuals receiving topiramate will demonstrate greater reductions in brain activity and drinking behavior compared to individuals receiving placebo. Individuals receiving placebo will exhibit responses similar to baseline responses.", 
            "measure": "fMRI response in the ventral striatum/medial orbitofrontal cortex during alcohol cue exposure", 
            "safety_issue": "No", 
            "time_frame": "baseline to after 6 weeks of study drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074904"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "change in drinking days from baseline to 9 weeks", 
                "measure": "Drinking days", 
                "safety_issue": "No", 
                "time_frame": "baseline and 9 weeks"
            }, 
            {
                "measure": "change in gamma-glutamyl transferase (GGT) or carbohydrate-deficient transferrin (CDT) levels", 
                "safety_issue": "No", 
                "time_frame": "baseline and Visit 9 (9 weeks)"
            }, 
            {
                "description": "change in number of heavy drinking days from baseline to 9 weeks", 
                "measure": "Heavy drinking days", 
                "safety_issue": "No", 
                "time_frame": "baseline to 9 weeks"
            }, 
            {
                "description": "change in mean alcohol consumption from baseline to 9 weeks", 
                "measure": "Mean alcohol consumption", 
                "safety_issue": "No", 
                "time_frame": "baseline to 9 weeks"
            }
        ], 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}